About this trial
The pilot study by Srp et al. (2021) proved that the SpiroGym app was feasible for supporting expiratory muscle strength training (EMST) in Parkinson's disease (PD) patients. Two weeks of intensive EMST coupled with SpiroGym were sufficient to significantly improve the participants' voluntary peak cough flow (PCF). The improvement was quantitatively comparable to the results of other intensive EMST studies with longer durations. When interpreting such rapid improvement, the impact of SpiroGym's visual feedback was considered. It was assumed that visual feedback increased training effort compared to regular training without immediate control. However, comparative studies were required to verify the possible additional effects of visual feedback on voluntary PCF compared to EMST without feedback.
Eligibility criteria
Qualifiers
Diagnosis of Parkinsons disease
Stable dopaminergic medication (stable dose for at least 1 month)
Disqualifiers
Other neurological disorders
Difficulty complying due to neuropsychological dysfunction (dementia with a score of less - - than 19 on the Montreal Cognitive Assessment)
Breathing disorders or diseases
Smoking in the past 5 years
Trial design
Treatments tested in this trial
- Expiratory muscle strength training + SpiroGym application
- Expiratory muscle strength training